EvoPAR-Prostate01: Phase III Clinical Trial Protocol for Saruparib in Prostate Cancer

A clinical trial protocol document for the EvoPAR-Prostate01 Phase III study evaluating saruparib in combination with androgen receptor pathway inhibitors for metastatic hormone-sensitive prostate cancer. The study plans to enroll approximately 1800 participants and began enrollment in November 2023. The document was authored by Arun A. Azad and is licensed under CC-BY-4.0.

Use Cases

• Analyzing clinical trial design and endpoints based on the described primary (rPFS) and secondary (OS) outcomes
• Studying patient cohort stratification based on the described HRRm and non-HRRm mutation groups
• Reviewing inclusion/exclusion criteria for patient selection modeling in metastatic hormone-sensitive prostate cancer trials

Strengths

• Document includes specific trial enrollment numbers: approximately 1800 participants (550 HRRm; 1250 non-HRRm)
• Provides clear primary and secondary endpoints: radiographic progression-free survival (rPFS) and overall survival (OS)
• Includes official clinical trial registration identifiers (NCT06120491, EU CT 2023-504214-30-00)

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• Data is a 242.4 KB document, indicating limited scope compared to raw patient datasets

Provenance

Source

figshare

Collection Method

Clinical trial protocol document authored by Arun A. Azad.

Time Range

Trial enrollment began in November 2023.

Freshness

Last updated 2026-04-14 10:00:03; freshness should be verified

Geography

Multicenter study; specific locations not stated.